Sentence examples for beta-adrenergic blocking agent from inspiring English sources

Beta-blocker, in full beta-adrenergic blocking agent, any of a group of synthetic drugs used in the treatment of a wide range of diseases and conditions of the sympathetic nervous system.

Thus, any resident who was prescribed one of these drugs and a beta-adrenergic blocking agent would have been flagged as having received a potentially inappropriate prescription.

Medication such as the beta-adrenergic blocking agent propranolol [ 31, 36– 39], reserpine [ 36] and the opiate fentanyl [ 40] all prevent FDG uptake in BAT, but the effect of benzodiazepines seems doubtful [ 35, 36, 40, 41].

Drugs used to treat these conditions include beta-adrenergic blocking agents (beta-blockers), which reduce excitatory reaction in response to sympathetic nervous system stimulation, and vasodilators.

This condition is easily controlled by a variety of physical or pharmacological approaches and can be prevented or reduced with beta-adrenergic blocking agents (beta blockers; drugs that diminish excitatory response) or calcium channel blocking agents.

Among these medications are ergotamine; beta-adrenergic blocking agents (beta blockers), notably propranolol (Inderal™) and timolol (Blocadren™); calcium channel blockers; and serotonin antagonists such as zolmitriptan (Zomig™), sumatriptan (Imitrex™), and methysergide (Sansert™).

Patients with atrial flutter are susceptible to marked increases in heart rate with relatively little stimulation unless treated pharmacologically with beta-adrenergic blocking agents, digitalis, or calcium channel blocking agents.

The contribution of the British pharmacologist Sir James Black to this field led to the development, first, of drugs that selectively block the effects of epinephrine and norepinephrine on the heart (beta blockers, or beta-adrenergic blocking agents) and, second, of drugs that block the effect of histamine on the stomach (H2-blocking agents), both of which are of major therapeutic importance.

Moreover, as yet unpublished preclinical studies from our group now suggest a place for beta-adrenergic blocking agents.

Subgroup analyses revealed no differences in strain and strain rate between hypertensive patients with and without beta-adrenergic blocking agents (data not shown).

Exclusion criteria for participation included age < 18 years, allergy to echocardiographic contrast agents or adenosine, previous history of coronary artery disease, chronic obstructive pulmonary disease and use of <span class="lh">beta-adrenergic blocking agents.